CRANBURY, N.J., July 26, 2019 /PRNewswire-PRWeb/ -- The Association for Value-Based Cancer Care (AVBCC) is delighted to announce that Scott Gottlieb, MD, former US Food and Drug Administration
As 23rd Commissioner of the FDA, Dr Gottlieb gained international recognition during his tenure for his aggressive advocacy in improving patients' healthcare access and for record numbers of approvals of innovative drugs and medical devices and affordable generic drugs. While he was at its head, the agency made groundbreaking advancements in gene therapies, targeted drugs, and digital health devices. Among his many accomplishments in office, he put in place policies to reduce death and disease from tobacco, improve food safety, and confront the addiction crises.
Dr Gottlieb is recognized as a leading thinker in the evolving healthcare and business nexus. In both 2018 and 2019 Fortune honored him as one of the "World's 50 Greatest Leaders." In its annual survey of 50 physician executives, Modern Healthcare named him one of the "Most Influential Physician Executives and Leaders" and in 2018 Time named Dr Gottlieb one of "50 People Transforming Healthcare."
He is a member of the National Academy of Medicine and a Resident Fellow at the American Enterprise Institute in Washington, DC. He has been published in top medical journals and has held editorial positions on The British Medical Journal and The Journal of the American Medical Association. He has written for general interest periodicals, including The Wall Street Journal, The New York Times, and The Washington Post, and appears regularly as a commentator on the cable television network CNBC.
Dr Gottlieb is returning to the private sector following an unparalleled term of leadership as one of the architects of today's healthcare landscape, and in his keynote address, "Opinions and Thoughts on the Future of Cancer Care in America," he will share insights he has gained through his long career at the forefront of change with the AVBCC Summit attendees.
"We are thrilled that Scott will be speaking at the Summit. He is a true visionary," said AVBCC Founder and Co-Chair Burt Zweigenhaft. Now in its 9th year, the AVBCC Summit brings together nationally recognized experts, faculty speakers, panelists, key opinion leaders, C-suite executives, and managers whose goals are to improve patient care and maximize patient access and outcomes through care coordination. "With our emphasis on sharing best practices and developing quality measures in the value-based cancer care arena, I can think of no one better to kick off this year's meeting."
Dr Gottlieb's address will be one of the highlights among the many anticipated during the 3 full days of planned workshops, panel discussions, sponsored knowledge exchanges, and impromptu conversations. Other scheduled speakers will be announced in the coming weeks. More information about the full agenda, presenters, and registration is available on the AVBCC Summit home page.
AVBCC was established nearly a decade ago to provide a network for payers and oncology healthcare professionals to interact and exchange knowledge to promote optimal care for patients and their families. It currently consists of more than 450 members and is the fastest growing national specialty organization dedicated to improving the care of cancer patients and their quality of life, by discussing, considering, and assessing the value equation as it relates to new and existing cancer therapies. For more information, go to http://www.valuebasedcancer.com/avbcc/about/.
The Lynx Group (TLG) is an Official Association Management Partner of AVBCC. TLG is a global strategic alliance of medical communication and education companies with headquarters in Cranbury, NJ. Employing a unique business model, the company provides pivotal and contemporary information and education for all stakeholders in healthcare.
SOURCE Association for Value-Based Cancer Care
Subscribe to our Free Newsletters!